Omega-3 long chain polyunsaturated fatty acids as a potential treatment for reducing dysmenorrhoea pain: Systematic literature review and meta-analysis.
docosahexaenoic acid
eicosapentanoic acid
fish oil
menstrual pain
menstruation
prostaglandins
Journal
Nutrition & dietetics: the journal of the Dietitians Association of Australia
ISSN: 1747-0080
Titre abrégé: Nutr Diet
Pays: Australia
ID NLM: 101143078
Informations de publication
Date de publication:
06 Aug 2023
06 Aug 2023
Historique:
revised:
17
06
2023
received:
21
03
2023
accepted:
03
07
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
6
8
2023
Statut:
aheadofprint
Résumé
This systematic literature review with meta-analysis aimed to determine the effect of omega-3 long chain polyunsaturated fatty acids on prostaglandin levels and pain severity in women with dysmenorrhoea and identify adverse side effects. A literature search was conducted in Embase, Scopus, Web of Science, MEDLINE complete, CINAHL and AMED databases (PROSPERO CRD42022340371). Included studies provided omega-3 long chain polyunsaturated fatty acids compared to a control in women with dysmenorrhoea and reported pain and/or prostaglandin levels. A random effects meta-analysis with Cohen's d effect size (95% confidence interval) was performed in SPPS for studies that reported pain outcomes. Study quality was assessed using the Academy of Nutrition and Dietetics Quality Criteria Checklist. Twelve studies (n = 881 dysmenorrhoeal women) of predominantly neutral quality (83%) were included that provided daily supplementation of 300-1800 mg omega-3 long chain polyunsaturated fatty acids over 2 or 3 months. Meta-analysis (n = 8 studies) showed a large effect of omega-3 long chain polyunsaturated fatty acids (d = -1.020, 95% confidence interval -1.53 to -0.51) at reducing dysmenorrhoea pain. No studies measured prostaglandin levels, 86% of studies measuring analgesic use showed a reduction with omega-3 long chain polyunsaturated fatty acids and few studies reported mild adverse side effects in individual participants. Findings suggest that daily supplementation of 300-1800 mg omega-3 long chain polyunsaturated fatty acids over 2-3 months are generally well tolerated and reduces pain and analgesic use in women with dysmenorrhoea. However, the neutral quality of research is limited by methodological issues and the mechanism of action remains to be determined.
Identifiants
pubmed: 37545015
doi: 10.1111/1747-0080.12835
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Nutrition & Dietetics published by John Wiley & Sons Australia, Ltd on behalf of Dietitians Australia.
Références
Al-Jefout M, Nawaiseh N. Continuous norethisterone acetate versus cyclical drospirenone 3 mg/ethinyl estradiol 20 μg for the management of primary dysmenorrhoea in young adult women. J Pediatr Adolesc Gynecol. 2016;29(2):143-147.
Bakhsh H, Algenaimi E, Aldhuwayhi R, AboWadaan M. Prevalence of dysmenorrhoea among reproductive age group in Saudi women. BMC Womens Health. 2022;22(1):78.
Polat A, Celik H, Gurates B, et al. Prevalence of primary dysmenorrhoea in young adult female university students. Arch Gynecol Obstet. 2009;279(4):527-532.
Hillen TI, Grbavac SL, Johnston PJ, Straton JA, Keogh JM. Primary dysmenorrhoea in young Western Australian women: prevalence, impact, and knowledge of treatment. J Adolesc Health. 1999;25(1):40-45.
Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. BMJ. 2006;332(7550):1134-1138.
Garland SM, Happo L, Jayasinghe YL, Gorelik A, Subasinghe AK, Wark JD. Prevalence and severity of dysmenorrhoea, and management options reported by young Australian women. Aust Fam Physician. 2016;45(11):829-834.
Harlow SD, Ephross SA. Epidemiology of menstruation and its relevance to women's health. Epidemiol Rev. 1995;17(2):265-286.
Armour M, Ferfolja T, Curry C, et al. The prevalence and educational impact of pelvic and menstrual pain in Australia: a National Online Survey of 4202 young women aged 13-25 years. J Pediatr Adolesc Gynecol. 2020;33(5):511-518.
Harel Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhoea in adolescents. Am J Obstet Gynecol. 1996;174(4):1335-1338.
Barcikowska Z, Rajkowska-Labon E, Grzybowska ME, Hansdorfer-Korzon R, Zorena K. Inflammatory markers in dysmenorrhoea and therapeutic options. Int J Environ Res Public Health. 2020;17(4):1191.
Lumsden MA, Kelly RW, Baird DT. Primary dysmenorrhoea: the importance of both prostaglandins E2 and F2α. Br J Obstet Gynaecol. 1983;90(12):1135-1140.
Lundström V, Gréen K. Endogenous levels of prostaglandin F2α and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol. 1978;130(6):640-646.
Strömberg MD, Åkerlund M, Forsling ML, Granström E, Kindahl H. Vasopressin and prostaglandins in premenstrual pain and primary dysmenorrhoea. Acta Obstet Gynecol Scand. 1984;63(6):533-538.
Dawood MY, Khan-Dawood FS. Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F2α in a randomized, double-blind, crossover treatment with placebo, acetaminophen, and ibuprofen in primary dysmenorrhoea. Am J Obstet Gynecol. 2007;196(1):35.e1-35.e5.
Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci U S A. 2002;99(21):13371-13373.
Armour M, Parry K, Al-Dabbas MA, et al. Self-care strategies and sources of knowledge on menstruation in 12,526 young women with dysmenorrhoea: a systematic review and meta-analysis. PLoS One. 2019;14(7):e0220103.
Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;2015(7):CD001751.
Mohammadi MM, Mirjalili R, Faraji A. The impact of omega-3 polyunsaturated fatty acids on primary dysmenorrhoea: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2022;78(5):721-731.
Meyer BJ, Mann NJ, Lewis JL, Milligan GC, Sinclair AJ, Howe PR. Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids. 2003;38(4):391-398.
Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000.
Moghadamnia AA, Mirhosseini N, Abadi MH, Omranirad A, Omidvar S. Effect of Clupeonella grimmi (anchovy/kilka) fish oil on dysmenorrhoea. East Mediterr Health J. 2010;16(4):408-413.
Trebble TM, Wootton SA, Miles EA, et al. Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation. Am J Clin Nutr. 2003;78(3):376-382.
Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2012;75(3):645-662.
Esmaillzadeh A, Azadbakht L. Major dietary patterns in relation to general obesity and central adiposity among Iranian women. J Nutr. 2008;138(2):358-363.
Chilton FH, Manichaikul A, Yang C, et al. Interpreting clinical trials with omega-3 supplements in the context of ancestry and FADS genetic variation. Front Nutr. 2022;8(8):808054.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Thomas J, Chandler J, Cumpston M, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022). Cochrane. 2022. http://www.training.cochrane.org/handbook
Academy of Nutrition and Dietetics. Evidence Analysis Manual. Academy of Nutrition and Dietetics; 2022.
Davaneghi S, Tarighat-Esfanjani A, Safaiyan A, Fardiazar Z. The effects of n-3 fatty acids and Rosa damascena extract on primary dysmenorrhea. Prog Nutr. 2017;19(1):34-40.
Demirturk F, Gungor T, Demirturk F, Akbayrak T, Aker EM. Relief of primary dysmenorrhea by supplementation with omega-3 fatty acids. Pain Clinic. 2002;14(1):81-84.
Mehrpooya M, Eshraghi A, Rabiee S, Larki-Harchegani A, Ataei S. Comparison the effect of fish-oil and calcium supplementation on treatment of primary dysmenorrhea. Rev Recent Clin Trials. 2017;12(3):148-153.
Rahbar N, Asgharzadeh N, Ghorbani R. Effect of omega-3 fatty acids on intensity of primary dysmenorrhea. Int J Gynaecol Obstet. 2012;117(1):45-47.
Sadeghi N, Paknezhad F, Rashidi Nooshabadi M, Kavianpour M, Rad SJ, Haghighian HK. Vitamin E and fish oil, separately or in combination, on treatment of primary dysmenorrhea: a double-blind, randomized clinical trial. Gynecol Endocrinol. 2018;34(9):804-808.
Sampalis F, Bunea R, Pelland MF, Kowalski O, Duguet N, Dupuis S. Evaluation of the effects of Neptune Krill Oil on the management of premenstrual syndrome and dysmenorrhea. Altern Med Rev. 2003;8(2):171-179.
Zafari M, Behmanesh F, Mohammadi AA. Comparison of the effect of fish oil and ibuprofen on treatment of severe pain in primary dysmenorrhea. Caspian J Intern Med. 2011;2(3):279-282.
Zafari M, Tofighi M, Aghamohammady A, Behmanesh F, Rakhshaee Z. Comparison of the effect of acupressure, fish oil capsules and ibuprofen on treatment of primary dysmenorrheal. Afr J Pharm Pharmacol. 2011;5(8):1115-1119.
Deutch B, Jørgensen EB, Hansen JC. Menstrual discomfort in Danish women reduced by dietary supplements of omega-3 PUFA and B12 (fish oil or sea oil capsules). Nutr Res. 2000;20(5):621-631.
Hosseinlou A, Alinejad V, Alinejad M, Aghakhani N. The effects of fish oil capsules and vitamin B1 tablets on duration and severity of dysmenorrhea in students of high school in Urmia-Iran. Glob J Health Sci. 2014;6(7):124-129.
Chen CX, Kwekkeboom KL, Ward SE. Self-report pain and symptom measures for primary dysmenorrhoea: a critical review. Eur J Pain. 2015;19(3):377-391.
Jensen MP. The Validity and Reliability of Pain Measures for Use in Clinical Trials in Adults. Review paper written for the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) meeting; April 12-13, 2003.
Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;2(3):355-374.
National Health and Medical Research Council, Australian Government Department of Health and Ageing, New Zealand Ministry of Health. Nutrient Reference Values for Australia and New Zealand. National Health and Medical Research Council; 2006.
International Society for the Study of Fatty Acids and Lipids. Report of the Sub-committee on Recommendations for Intake of Polyunsaturated Fatty Acids in Healthy Adults. International Society for the Study of Fatty Acids and Lipids; 2004.
National Heart Foundation of Australia. Dietary Position Statement. Fish, Seafood & Heart Healthy Eating. National Heart Foundation of Australia; 2015.
Yokoyama E, Takeda T, Watanabe Z, et al. Association of fish intake with menstrual pain: a cross-sectional study of the Japan Environment and Children's Study. PLoS One. 2022;17(7):e0269042.
Meyer BJ. Australians are not meeting the recommended intakes for omega-3 long Chain polyunsaturated fatty acids: results of an analysis from the 2011-2012 National Nutrition and Physical Activity Survey. Nutrients. 2016;8(3):111.
James MJ, Sullivan TR, Metcalf RG, Cleland LG. Pitfalls in the use of randomised controlled trials for fish oil studies with cardiac patients. Br J Nutr. 2014;112(5):812-820.
de Groot RH, Emmett R, Meyer BJ. Non-dietary factors associated with n-3 long-chain PUFA levels in humans - a systematic literature review. Br J Nutr. 2019;121(7):793-808.
Armour M, Ee CC, Naidoo D, et al. Exercise for dysmenorrhoea. Cochrane Database Syst Rev. 2019;9(9):CD004142.
Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56(8):365-379.
Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res. 2008;47(2):147-155.
Lange KW, Nakamura Y, Gosslau AM, Shiming L. Are there serious adverse effects of omega-3 polyunsaturated fatty acid supplements? J Food Bioact. 2019;7:1-6.
Heller M, Gemming L, Tung C, Grant R. Oxidation of fish oil supplements in Australia. Int J Food Sci Nutr. 2019;70(5):540-550.